Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Tesco launches the super tomato
The tomato is the product of cross-breading by British farmers keen to utilize the potential of different varieties. The creation, which contains nearly double the amount of lycopene
The tomato is the product of cross-breading by British farmers keen to utilize the potential of different varieties. The creation, which contains nearly double the amount of lycopene
Both a community pharmacist and a member of the public complained to the MHRA on March 20, 2006 about the free offer of medicines as an ‘on-the-shelf’ sales
A fungus, called Fusarium, is thought to cause the infection that has so far been found in 109 people and is being investigated by public health authorities in
The phase I clinical trial is designed as a double blind, single dose-escalation study and will be conducted at Sourasky Medical Center in Tel Aviv. BL-1020 is an
In a series of reports on ‘disease-mongering’, the Public Library of Science Medicine suggests that pharmaceutical companies intentionally widen the boundaries of illness in order to expand the
Approximately 130,000 multiple sclerosis (MS) patients are receiving either FDA-approved interferon beta-1a weekly (Biogen Idec’s Avonex) or glatiramer acetate daily (Teva’s Copaxone) to treat relapsing forms of MS.
Anna Bligh, Queensland deputy premier, treasurer and minister for state development, trade and innovation, has announced a $865,000 grant for the University of Queensland’s (UQ) Centre for Integrated
Based on available efficacy data, the independent data monitoring board said that enrollment should be terminated under the current protocol as it saw “very little chance for significant
The unique properties of the hollow shell nano-particles, known as polymersomes, allow them to deliver two distinct drugs, paclitaxel (marketed as Taxol by Bristol-Myers Squibb), and doxorubicin directly
The trial met the primary efficacy endpoint of improved exercise capacity for both ambrisentan dose groups, with a good safety profile and no observed liver function abnormalities in